BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

Akeso Reports Positive Phase 3 Results For Gumokimab In Ankylosing Spondylitis And Manfidokimab In Atopic Dermatitis

Akeso Inc. announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibod...

August 26, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025

The first eight months of 2025 have been transformative for biosupplier technologies worldwide. From innovative lab reagents and biomaterials to ad...

August 22, 2025 | Analysis

Akeso Doses First Patient in Phase III COMPASSION-33 Trial of Cadonilimab for Perioperative Gastric Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-31...

August 21, 2025 | News

RemeGen and Santen Form Strategic Alliance on RC28-E for Asia and Greater China

RemeGen Co., a leading Chinese biopharmaceutical company, announced that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Sa...

August 20, 2025 | News

Ascletis’ ASC47 Plus Tirzepatide Shows 87% Greater Weight Loss Than Tirzepatide Alone in Preclinical Obesity Study

The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to t...

August 13, 2025 | News

Codex Genetics and Pacific Edge Partner to Introduce Cxbladder Genomic Urine Tests for Bladder Cancer Diagnosis in Hong Kong

Codex Genetics, one of the leading precision diagnostics companies in Hong Kong, announced an exclusive collaboration with Pacific Edge, the deve...

August 11, 2025 | News

AXA Partners with Hainan Boao Lecheng to Pioneer Innovative Cross-Border Medical Insurance Models

AXA China Region Insurance Company (Bermuda) Limited ("AXA") formally signed an official cooperation agreement with Hainan Boao Lecheng Internati...

August 11, 2025 | News

XtalPi and DoveTree Medicines Forge $5.99 Billion AI-Powered Drug Discovery Alliance

XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced ...

August 07, 2025 | News

GenScript Biotech Earns MSCI AA ESG Rating, Recognised as Global Sustainability Leader

GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that its ESG rating...

August 04, 2025 | News

Akeso Enrols First Patient in Phase III Trial of Ivonescimab for Metastatic Pancreatic Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase II...

July 24, 2025 | News

WuXi Biologics China PFS Site Clears FDA Inspection

WuXi Biologics’ pre-filled syringes (PFS) commercial production line passed its first FDA inspection, paving the way for global delivery of high-qu...

July 22, 2025 | News

Akeso Begins Phase III Trial of Ivonescimab for Hard-to-Treat Advanced Colorectal Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phas...

July 16, 2025 | News

Ascletis Completes Dosing in U.S. Trial of ASC47 and Semaglutide for Obesity

The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day ...

July 15, 2025 | News

Stay Connected